Cargando…

Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy

Type 2 diabetes mellitus (T2DM) is an emerging epidemic in Asian countries, especially in India. With the advent of the SGLT2 inhibitor class of drugs demonstrating benefits beyond glycemic control, viz. weight loss, blood pressure reduction, and cardiovascular and renal protection, the management o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohan, Viswanathan, Mithal, Ambrish, Joshi, Shashank R, Aravind, S R, Chowdhury, Subhankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322139/ https://www.ncbi.nlm.nih.gov/pubmed/32612352 http://dx.doi.org/10.2147/DDDT.S221093

Ejemplares similares

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
por: Napolitano, Antonella, et al.
Publicado: (2013)

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
por: Mudaliar, Sunder, et al.
Publicado: (2012)

Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin
por: Dobbins, Robert, et al.
Publicado: (2021)

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
por: Hussey, Elizabeth K, et al.
Publicado: (2013)

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
por: Dharmalingam, Mala, et al.
Publicado: (2020)

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
por: Kapur, Anita, et al.
Publicado: (2013)

Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries
por: Dutt, Chaitanya, et al.
Publicado: (2022)

Expert Consensus Recommendations on Time in Range for Monitoring Glucose Levels in People with Diabetes: An Indian Perspective
por: Mohan, Viswanathan, et al.
Publicado: (2023)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
por: Mohan, Viswanathan, et al.
Publicado: (2019)

Hypoglycemia in type 2 diabetes: Standpoint of an experts’ committee (India hypoglycemia study group)
por: Viswanathan, Mohan, et al.
Publicado: (2012)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India
por: Wasir, Jasjeet S., et al.
Publicado: (2018)

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation
por: Attimarad, Mahesh, et al.
Publicado: (2021)

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
por: Jain, Rajesh, et al.
Publicado: (2022)

Methodology and feasibility of a structured education program for diabetes education in India: The National Diabetes Educator Program
por: Joshi, Shilpa, et al.
Publicado: (2013)

Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
por: Kaur, Parjeet, et al.
Publicado: (2016)

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial
por: Joshi, Deepa, et al.
Publicado: (2022)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
por: Tampucci, Silvia, et al.
Publicado: (2023)

Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness
por: Attimarad, Mahesh, et al.
Publicado: (2021)

Gestational diabetes in India: Science and society
por: Mithal, Ambrish, et al.
Publicado: (2015)

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
por: Bawa, Tarunika, et al.
Publicado: (2013)

Two‐year trends from the LANDMARC study: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcome in patients with type 2 diabetes mellitus
por: Das, Ashok K., et al.
Publicado: (2023)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
por: Gomez-Peralta, Fernando, et al.
Publicado: (2019)

Dietary beliefs and eating patterns influence metabolic health in type 2 diabetes: A clinic-based study in urban North India
por: Colles, Susan L., et al.
Publicado: (2013)

Puberty and type 1 diabetes
por: Chowdhury, Subhankar
Publicado: (2015)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

One‐year trends from the LANDMARC trial: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcomes of type 2 diabetes mellitus
por: Das, Ashok K., et al.
Publicado: (2021)

Loteprednol etabonate: Dematiaceous fungal colonisation by Bipolaris species in the left eye: case report
Publicado: (2020)

Insights on Medical Nutrition Therapy for Type 2 Diabetes Mellitus: An Indian Perspective
por: Viswanathan, Vijay, et al.
Publicado: (2019)

The LongitudinAl Nationwide stuDy on Management And Real‐world outComes of diabetes in India over 3 years (LANDMARC trial)
por: Das, Ashok K., et al.
Publicado: (2023)

SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients - a Real World Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2020)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India
por: Kaur, Parjeet, et al.
Publicado: (2014)

Vitamin D supplementation in pregnancy
por: Mithal, Ambrish, et al.
Publicado: (2014)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u1vpapcfjf3po79fbp8nijd2cc